StockData
IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

IDEXX LABORATORIES INC /DE

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$555.80−4.56 (-0.81%)

Close on Oct 19, 2026

Market cap
$44.08B
P/E (TTM)
39.1
Dividend yield
–

Idexx Laboratories statistics

Financials through Jun 30, 2026, price as of Oct 19, 2026, median of In Vitro & In Vivo Diagnostic Substances companies for comparison

Valuation

MeasureIdexx LaboratoriesIndustry median
Market Cap$43.79B$166.30M
Enterprise Value$44.04B$88.19M
PE Ratio39.0920.44
PS Ratio9.623.65
PB Ratio27.152.03
P/TBV Ratio39.682.29
P/FCF Ratio34.9117.44
P/OCF Ratio31.9312.98

Enterprise value

MeasureIdexx LaboratoriesIndustry median
EV / Sales9.672.51
EV / EBITDA27.3114.65
EV / EBIT30.1919.00
EV / FCF35.1120.86

Income (trailing twelve months)

MeasureIdexx LaboratoriesIndustry median
Revenue$4.55B$58.34M
Gross Profit$2.84B$105.94M
Operating Income$1.46B-$21.40M
Pretax Income$1.42B-$14.34M
Net Income$1.14B-$22.46M
EBITDA$1.61B-$16.91M
EPS (Diluted)$14.22-$0.83

Margins

MeasureIdexx LaboratoriesIndustry median
Gross Margin62.4%52.9%
Operating Margin32.0%-44.0%
Pretax Margin31.3%-13.3%
Profit Margin25.0%-40.2%
EBITDA Margin35.4%-30.2%
FCF Margin27.5%-9.27%

Returns

MeasureIdexx LaboratoriesIndustry median
Return on Equity (ROE)74.2%-53.2%
Return on Assets (ROA)33.7%-40.9%
Return on Invested Capital (ROIC)63.3%-32.4%
Return on Capital Employed (ROCE)67.7%-38.1%

Growth

MeasureIdexx LaboratoriesIndustry median
Revenue Growth (YoY)12.8%5.96%
Net Income Growth (YoY)15.6%-35.2%
EPS Growth (YoY)18.4%-26.2%
FCF Growth (YoY)59.9%2.34%
Revenue Growth (3Y CAGR)8.52%2.25%
Revenue Growth (5Y CAGR)9.72%6.48%
EPS Growth (3Y CAGR)17.7%-0.17%
EPS Growth (5Y CAGR)14.3%3.77%

Balance sheet

MeasureIdexx LaboratoriesIndustry median
Cash & Short-Term Investments$196.93M$61.43M
Total Debt$449.86M$118.52M
Net Cash (Debt)-$252.93M$15.35M
Net Cash Per Share-$3.21$0.66
Equity (Book Value)$1.61B$49.09M
Book Value Per Share$20.47$1.37
Tangible Book Value$1.10B$23.52M
Working Capital$221.82M$76.81M

Financial position

MeasureIdexx LaboratoriesIndustry median
Current Ratio1.173.34
Quick Ratio0.642.44
Debt / Equity0.280.52
Debt / EBITDA0.283.44
Debt / FCF0.364.89
Net Debt / EBITDA0.162.36
Interest Coverage38.60-6.26

Cash flow (trailing twelve months)

MeasureIdexx LaboratoriesIndustry median
Operating Cash Flow$1.37B-$12.35M
Capital Expenditures-$117.18M-$1.08M
Free Cash Flow$1.25B-$20.22M
FCF Per Share$15.92-$0.42

Efficiency

MeasureIdexx LaboratoriesIndustry median
Asset Turnover1.340.39
Inventory Turnover4.362.70
Revenue Per Employee$413.93K$404.87K
Profits Per Employee$103.61K-$703.34K
Employee Count11,00074

Dividends and yields

MeasureIdexx LaboratoriesIndustry median
Earnings Yield2.60%-23.3%
FCF Yield2.86%-8.72%
Buyback Yield2.69%-0.59%
Shareholder Yield2.69%0.00%

Shares

MeasureIdexx LaboratoriesIndustry median
Shares Outstanding78,781,10058,127,000
Shares Change (YoY)-2.40%10.9%
Shares Change (QoQ)-0.46%0.54%
Float78,548,10049,136,700
Shares Held by Insiders0.30%11.6%
Shares Held by Institutions94.5%59.4%

Taxes

MeasureIdexx LaboratoriesIndustry median
Income Tax$284.76M$79.87K
Effective Tax Rate20.0%20.6%

Scores

MeasureIdexx LaboratoriesIndustry median
Graham Number$80.93$18.73
Graham Upside-85.4%-45.1%
Altman Z-Score20.01-0.22
Piotroski F-Score84
Beneish M-Score-2.50-2.62

Calculated by StockData from Idexx Laboratories's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.